Quantitative 7T phase imaging in premanifest Huntington disease
- PMID: 24742810
- PMCID: PMC4425411
- DOI: 10.3174/ajnr.A3932
Quantitative 7T phase imaging in premanifest Huntington disease
Abstract
Background and purpose: In vivo MR imaging and postmortem neuropathologic studies have demonstrated elevated iron concentration and atrophy within the striatum of patients with Huntington disease, implicating neuronal loss and iron accumulation in the pathogenesis of this neurodegenerative disorder. We used 7T MR imaging to determine whether quantitative phase, a measurement that reflects both iron content and tissue microstructure, is altered in subjects with premanifest Huntington disease.
Materials and methods: Local field shift, calculated from 7T MR phase images, was quantified in 13 subjects with premanifest Huntington disease and 13 age- and sex-matched controls. All participants underwent 3T and 7T MR imaging, including volumetric T1 and 7T gradient recalled-echo sequences. Local field shift maps were created from 7T phase data and registered to caudate ROIs automatically parcellated from the 3T T1 images. Huntington disease-specific disease burden and neurocognitive and motor evaluations were also performed and compared with local field shift.
Results: Subjects with premanifest Huntington disease had smaller caudate volume and higher local field shift than controls. A significant correlation between these measurements was not detected, and prediction accuracy for disease state improved with inclusion of both variables. A positive correlation between local field shift and genetic disease burden was also found, and there was a trend toward significant correlations between local field shift and neurocognitive tests of working memory and executive function.
Conclusions: Subjects with premanifest Huntington disease exhibit differences in 7T MR imaging phase within the caudate nuclei that correlate with genetic disease burden and trend with neurocognitive assessments. Ultra-high-field MR imaging of quantitative phase may be a useful approach for monitoring neurodegeneration in premanifest Huntington disease.
© 2014 by American Journal of Neuroradiology.
Figures





References
-
- Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369–84 - PubMed
-
- Li SH, Li XJ. Huntingtin and its role in neuronal degeneration. Neuroscientist 2004;10:467–75 - PubMed
-
- Bohanna I, Georgiou-Karistianis N, Hannan AJ, et al. . Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008;58:209–25 - PubMed
-
- Aylward EH, Codori AM, Rosenblatt A, et al. . Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552–60 - PubMed
-
- Rosas HD, Goodman J, Chen YI, et al. . Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001;57:1025–28 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R37 AG031220/AG/NIA NIH HHS/United States
- 1S10RR026845-01/RR/NCRR NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- S10 RR026845/RR/NCRR NIH HHS/United States
- N01-NS-0-2328/NS/NINDS NIH HHS/United States
- AG031220/AG/NIA NIH HHS/United States
- R01 AG-031189/AG/NIA NIH HHS/United States
- P01 AG021601/AG/NIA NIH HHS/United States
- T32 AG023481/AG/NIA NIH HHS/United States
- AG021601/AG/NIA NIH HHS/United States
- R01 AG-031189-6/AG/NIA NIH HHS/United States
- R01 AG031189/AG/NIA NIH HHS/United States
- K23 AG037566/AG/NIA NIH HHS/United States
- K23 AG021989/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources